Literature DB >> 35361722

The Search for the Perfect Agent for Anemia Management in Chronic Kidney Disease.

Francesco Locatelli1, Lucia Del Vecchio2.   

Abstract

Entities:  

Keywords:  HIF PH inihibitors; anemia; chronic kidney disease; dialysis; erythropoiesis stimulating agents; erythropoietin; roxadustat

Mesh：

Year:  2022        PMID： 35361722      PMCID： PMC8970449          DOI： 10.1681/ASN.2022020173

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   14.978


× No keyword cloud information.
  7 in total

Review 1.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.

Authors:  Glenn M Chertow; Pablo E Pergola; Youssef M K Farag; Rajiv Agarwal; Susan Arnold; Gabriel Bako; Geoffrey A Block; Steven Burke; Fausto P Castillo; Alan G Jardine; Zeeshan Khawaja; Mark J Koury; Eldrin F Lewis; Tim Lin; Wenli Luo; Bradley J Maroni; Kunihiro Matsushita; Peter A McCullough; Patrick S Parfrey; Prabir Roy-Chaudhury; Mark J Sarnak; Amit Sharma; Bruce Spinowitz; Carol Tseng; James Tumlin; Dennis L Vargo; Kimberly A Walters; Wolfgang C Winkelmayer; Janet Wittes; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2021-04-29       Impact factor: 91.245

3.  Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.

Authors:  Steven Fishbane; Carol A Pollock; Mohamed El-Shahawy; Elizabeth T Escudero; Anjay Rastogi; Bui Pham Van; Lars Frison; Mark Houser; Maksym Pola; Dustin J Little; Nicolas Guzman; Pablo E Pergola
Journal:  J Am Soc Nephrol       Date:  2022-04       Impact factor: 10.121

Review 4.  The stimulation of thrombosis by hypoxia.

Authors:  Neha Gupta; You-Yang Zhao; Colin E Evans
Journal:  Thromb Res       Date:  2019-07-15       Impact factor: 3.944

5.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

6.  Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.

Authors:  Nan Chen; Chuanming Hao; Bi-Cheng Liu; Hongli Lin; Caili Wang; Changying Xing; Xinling Liang; Gengru Jiang; Zhengrong Liu; Xuemei Li; Li Zuo; Laimin Luo; Jianqin Wang; Ming-Hui Zhao; Zhihong Liu; Guang-Yan Cai; Li Hao; Robert Leong; Chunrong Wang; Cameron Liu; Thomas Neff; Lynda Szczech; Kin-Hung P Yu
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245

7.  Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.

Authors:  Jonathan Barratt; Wladyslaw Sulowicz; Michael Schömig; Ciro Esposito; Michael Reusch; James Young; Botond Csiky
Journal:  Adv Ther       Date:  2021-09-14       Impact factor: 3.845
  7 in total
  1 in total

1.  Clinical Management of Hemodialyzed Patients: From Pharmacological Interventions to Advanced Technologies.

Authors:  Paolo Monardo; Antonio Lacquaniti
Journal:  J Clin Med       Date:  2022-07-25       Impact factor: 4.964
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.